Berberine, ALA, Omega 3s Berberine is a plant-derived compound with evidence supporting improvements in insulin sensitivity, fat metabolism, and lipid profiles addressing some of the same downstream metabolic issues that AOD-9604 targets
In experimental models of Wilson disease, copper accumulates in the nuclear region of hepatocytes, where these metabolic nuclear receptors are primarily located [130]
Using both together produces an additive benefit as demonstrated in the original Dhurat 2013 trial and now confirmed across multiple pooled studies
Cagrilintide vs AOD 9604 Mechanism: Cagrilintide: Amylin receptor agonist (appetite/satiety) AOD 9604: HGH fragment (fat metabolism) Completely different Weight loss: Cagrilintide: 10-12% body weight AOD 9604: 5-8% body weight (less robust data) Cagrilintide superior Clinical evidence: Cagrilintide: Extensive Phase 2/3 trials AOD 9604: Limited clinical data Cagrilintide better studied Side effects: Cagrilintide: GI effects common AOD 9604: Minimal side effects AOD 9604 better tolerated Combination potential: Could theoretically combine (different mechanisms) No clinical data on combination Cagrilintide + semaglutide better established Verdict: Cagrilintide more powerful, better evidence
The bioavailability of glutathione, when taken orally, is below one percent due to enzymatic degradation and poor gastrointestinal absorption 3
On one hand, BPC-157 might reduce some of the bleeding risks associated with these medications